Amaris Health Economics & Market Access, London, England, UK.
ICON Plc, Vancouver, British Columbia, Canada.
Value Health. 2019 Oct;22(10):1178-1186. doi: 10.1016/j.jval.2019.05.013. Epub 2019 Aug 23.
Network meta-analysis (NMA) techniques allow the comparison of a complete set of interventions for patient groups. These meta-analysis techniques may be the only source of evidence to underpin estimates of comparative efficacy. Reimbursement agencies around the world are increasingly reliant upon meta-analysis techniques and assess their design and conduct with growing sophistication.
Our objective is to create a superset of requirements collated from available national guidelines for the conduct of network meta-analysis such that a single analysis may be conducted to satisfy all reimbursement bodies that have specified requirements in sufficient detail.
Published and draft guidelines documents from reimbursement bodies and health technology appraisal agencies were examined for their stipulations as to the conduct and design of network meta-analysis and measures to be taken to reduce bias and increase validity.
Guidelines from 41 countries were reviewed, yielding a sample size of 13 countries' guideline documents: Australia, Belgium, Canada, China, Ireland, England and Wales, France, Germany, Scotland, South Africa, South Korea, Spain, Thailand, and a guideline document from the European Network of Health Technology Assessment, which contained explicit recommendations or requirements for conduct of NMA.
This study expands the range of previous work that reviewed the guidelines for the use of indirect evidence from multiple national jurisdictions. These aggregate guidelines do not include requirements that are mutually prohibitive. It is possible to perform a single NMA for submission to an expanded list of national jurisdictions.
网络荟萃分析(NMA)技术允许对一组完整的患者群体干预措施进行比较。这些荟萃分析技术可能是支持比较疗效估计的唯一证据来源。全球范围内的报销机构越来越依赖荟萃分析技术,并越来越复杂地评估其设计和实施。
我们的目标是创建一套从现有的国家指南中收集的要求,以便进行单一分析,以满足所有有具体要求且规定足够详细的报销机构。
检查了来自报销机构和卫生技术评估机构的已发表和草案指南文件,以了解其对网络荟萃分析的实施和设计的规定,以及为减少偏差和提高有效性而采取的措施。
审查了 41 个国家的指南,得出了 13 个国家指南文件的样本量:澳大利亚、比利时、加拿大、中国、爱尔兰、英格兰和威尔士、法国、德国、苏格兰、南非、韩国、西班牙、泰国,以及一份来自欧洲卫生技术评估网络的指南文件,其中包含了对 NMA 进行的明确建议或要求。
本研究扩展了之前从多个国家司法管辖区审查间接证据使用指南的工作范围。这些综合指南不包括相互禁止的要求。有可能对提交给更多国家司法管辖区的单一 NMA 进行。